YARW · YARROW BIOSCIENCE INC
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
Market Cap
212.2M
52 Wk Range
$12.38 - $46.95
Previous Close
$13.93
Open
$13.93
Volume
135,067
Day Range
$13.53 - $14.89
Enterprise Value
129.2M
Cash
22.93M
Avg Qtr Burn
N/A
Insider Ownership
2.02%
Institutional Own.
46.58%
Qtr Updated
Jun 30th 2026
